Radiolabeled monoclonal antibodies have been used with encouraging results in conjunction with stem cell transplantation for patients with hematologic malignancies targeting a variety of surface antigens including CD33, CD45 and CD66 for leukemias, CD20 and CD22 for non-Hodgkin's lymphomas, and ferritin for Hodgkin's disease. The results obtained targeting epithelial antigens on solid tumors, however, have generally been less encouraging, primarily due to the relative insensitivity of these malignancies to ionizing radiation. In this report we review clinical studies that have incorporated myeloablative doses of targeted radiation using radiolabeled antibodies in conjunction with stem cell transplant regimens.
Despite significant advances in radiation therapy and chemotherapeutic reagents over the past quarter of a century, few randomized studies have been conducted comparing transplant conditioning regimens, and no consensus has been reached on the optimal regimen for leukemias or lymphomas. External beam total body irradiation (TBI) has commonly been used in many preparative regimens for conventional stem cell transplant procedures because of its ability to irreversibly damage DNA, and thus inhibit replication of malignant cells. 1 Unfortunately, many patients receiving high doses of chemoradiotherapy in conjunction with allogeneic or autologous stem cell transplantation still die from recurrent disease. Attempts to further increase the doses of the components of the preparative regimen in order to maximize cytoreduction have not been feasible due to lethal toxicities. Recent work exploiting the safety and efficacy of unconjugated monoclonal antibodies (mAbs) that target specific surface antigens on malignant cells has been incorporated into a new generation of novel treatment approaches using stem cell transplantation. 'Naked' mAbs have been employed to purge autologous marrow grafts in attempts to eradicate contaminating tumor cells in vitro, which may impact disease progression, the greatest risk following autologous stem cell transplantation. 2 In vivo purging attempts have also been investigated to increase transplant efficiency in both pre-transplant and post-transplant adjuvant settings. [3] [4] [5] Because relapse rates remain high following syngeneic and allogeneic transplantation, it follows that most relapses occur due to the failure to eradicate malignant cells in the patient, and are not solely due to reinfusion of tumor cells contaminating the stem cell graft. Therefore, the development of more potent conditioning regimens and exploration of alternative immunotherapy strategies remain high priorities for therapy of both hematologic and solid tumor malignancies.
In vitro experiments using sublethal doses of ionizing radiation show a low level of cytotoxicity for most solid tumor cell lines, likely due to a significant ability to repair radiation-induced DNA damage. 6 In contrast, hematologic malignancies are relatively radiosensitive due, at least in part, to a limited ability to repair sublethal cell injury. Consequently, hematologic malignancies classically display a steep dose-response curve with no 'plateau' in survival at low radiation doses. Several investigators have thus focused on targeted radioimmunotherapy (RIT) delivered at myeloablative doses as a component of preparative regimens prior to stem cell transplantation to improve cure rates and reduce normal organ toxicities. RIT is a therapeutic modality that uses mAbs as vehicles for the delivery of radiation to malignant cells by binding to tumor-associated antigens. In contrast to external beam radiation therapy, targeting of the tumor by mAbs can specifically deliver radiation to multiple tumor sites throughout the body, with less exposure of normal organs to radiation (Table 1) . Compared to standard fractionated external beam TBI, radiolabeled antibodies expose malignant cells to a continuous, exponentially decreasing low-dose rate of radiation exposure for long periods of time. It is likely that the ability of a cell to repair itself is greatly compromised when exposed to continuous radiation from a naturally decaying radioisotope, resulting in the accumulation of DNA damage resulting in cell death. In contrast to unmodified mAb and drug/toxin mAb conjugates, radiolabeled antibodies do not need to bind to every tumor cell, or penetrate homogeneously into tumor cell masses, since the ionizing energy from ␤ particles emitted from therapeutic isotopes are cap- Table 2 ). Moreover, RIT does not depend on host effector mechanisms such as antibody-dependent cellular cytotoxicity, which may be impaired in patients with hematologic malignancies and/or limited in the setting of a large tumor burden.
The most appropriate radioisotope for use in RIT remains controversial; although a variety of ␤ emitting isotopes have been employed into several non-myeloablative RIT trials,
90
Y and 131 I have primarily been incorporated into most transplant regimens to date (Table 3) . Iodine-131 emits ␥ particles that are useful for radioimmunoscintigraphy, in addition to therapeutic ␤ particles. Studies examining the use of 131 I-mAb conjugates created using conventional labeling techniques, however, are most appropriately limited to targeting antigens that do not internalize after binding, since endocytosis leads to intracellular catabolism and subsequent excretion of free 131 I and 131 I-tyrosine. [8] [9] [10] Conversely, 90 Y is believed to be retained inside the cell for 
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Leukemia
Previous work by Clift et al 11, 12 determined that increasing the TBI dose from 12 to 15.75 Gy in transplant preparative regimens could significantly decrease post-transplant relapse of acute and chronic myeloid malignancies. This improvement, however, came at the cost of increased nonrelapse mortality. Consequently, the anti-leukemic effects of radioimmunoconjugates that selectively deliver irradiation to targeted leukemic blasts, with less toxicity inflicted on normal tissues, have been investigated as therapy for myeloid malignancies in the hope that cure rates could be significantly improved (Table 4) . CD33 is an attractive target for immunotherapy of myeloid leukemia since it is expressed on most myeloid leukemic blasts, but not on hematopoietic stem cells. [13] [14] [15] Anti-CD33 antibodies rapidly saturate CD33 antigenic targets and the antibody- Table 4 Selected trials using myeloablative doses of radioimmunoconjugates and stem cell transplantation to treat leukemias CR ϭ complete response ϭ no evidence of disease for у1 month; TRM ϭ treatment-related mortality; Cy ϭ cyclophosphamide; TBI ϭ total body irradiation; Bu ϭ busulfan; TT ϭ thiotepa; AML ϭ acute myeloid leukemia; ALL ϭ acute lymphocytic leukemia; MDS ϭ myelodysplastic syndrome; OS ϭ overall survival; DFS ϭ disease-free survival; Gy ϭ gray.
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antigen complexes are rapidly internalized into the cell. Studies done at the Memorial Sloan-Kettering Cancer Center (MSKCC) demonstrated that unconjugated humanized anti-CD33 IgG2a antibody (HuM195) has activity against myeloid blasts and that the antibody was well tolerated. 16, 17 These early studies using unconjugated anti-CD33 mAb did not demonstrate significant responses in patients who had a relatively high leukemic disease burden. These results did suggest, however, that the outcome of marrow transplantation for leukemia might be improved by selectively delivering radiation to the marrow, gaining the therapeutic advantage of the higher dose regimen without significantly increasing toxicity. Based on this principle, a pilot study from the Fred Hutchinson Cancer Research Center by Appelbaum et al 18 employed anti-CD33 antibody (p67) radioiodinated with 131 I as part of a marrow transplant preparative regimen for patients with recurrent or refractory acute myeloid leukemia (AML). In this study, serial quantitative gamma camera imaging was used to estimate the dose delivered to bone marrow and spleen relative to other vital organs. Favorable biodistributions of radiolabeled antibody were found in four of nine patients enrolled in this small study; the marrow and spleen in these four patients were found to absorb greater amounts of radioactivity than the liver, lungs, or kidneys. Failure to achieve favorable biodistributions in the other five patients was attributed to the brief residence time of 131 I in the marrow space. The short marrow residence time of the radionuclide was probably due to the rapid internalization and degradation of the 131 I-anti-CD33 immunoconjugate with extrusion of small molecular weight 131 I-metabolites from the cell. Patients with favorable biodistributions of radiolabeled antibody, defined as those in whom estimated radiation doses to marrow and spleen were higher than to any normal organ, then received the therapeutic 131 I-labeled anti-CD33 antibody. The anti-CD33 antibody was labeled with the amount of 131 I estimated to deliver a predetermined dose to the normal organ receiving the highest radiation dose (110 to 330 mCi). In addition to 131 I-p67, patients received a standard conditioning regimen with cyclophosphamide (CY; 120 mg/kg) and 12 Gy of TBI. Dose escalation was limited by the amount of 131 I with which optimum doses of antibody could be labeled, without adversely affecting antibody immunoreactivity. Jurcic et al 19 further investigated myeloablative doses (120-230 mCi/m 2 ) of 131 I-M195 (the murine precursor from which HuM195 was derived) and 131 I-HuM195 with 16 mg/kg of busulfan (BU) and 120 mg/kg of CY, followed by HLA-compatible bone marrow for 30 patients with advanced AML or chronic myelogenous leukemia (CML). Remissions were achieved in 27 of 30 patients with little toxicity related to the radioisotope and without engraftment complications.
Because of the limitations targeting the internalizing CD33 antigen when using conventionally iodinated antibody, 90 Y-HuM195 has been explored in a phase I trial by the MSKCC group. 20 The data suggest that 90 Y-HuM195 has anti-leukemic activity and that the 90 Y isotope may reside for a prolonged period of time at leukemic sites and in marrow, but that its therapeutic use will require stem cell rescue. A study by the same group incorporating 90 YHuM195 and etoposide or BU/CY in a stem cell preparative transplant regimen is currently on going. The Seattle group and collaborators from Wyeth-Ayerst Research and Lederle Laboratories (Madison, NJ, USA) have developed and tested a potent immunoconjugate, gemtuzumab ozogamacin (Myelotarg) derived by combining the anti-tumor antibiotic calicheamicin with the humanized p67 anti-CD33 mAb. This immunoconjugate also takes advantage of the rapid internalization of the anti-CD33 antibody-antigen complex. 21 Because of its safety and efficacy profile, Myelotarg has been approved for the treatment of CD33 ϩ AML patients in first relapse, who are over the age of 60 and not considered candidates for more aggressive forms of therapy. 22, 23 Current studies are exploring the use of Myelotarg in combination with conventional chemotherapy in remission induction therapy, and as a single agent for remission maintenance.
Other alternative targets for RIT that do not modulate upon antibody interaction are currently being explored, including the CD45 antigen. CD45 is expressed by the vast majority of hematologic malignancies, including 85-90% of acute lymphoid and myeloid leukemias, and is not found on tissues of non-hematopoietic origin. 24, 25 Matthews et al 26 have achieved encouraging phase I results using 131 I-anti-CD45 mAb (BC8) combined with a transplant regimen employing 120 mg/kg CY and 12 Gy TBI for therapy of acute leukemias. Biodistribution of trace-labeled antibody was initially determined in 41 patients with advanced AML or acute lymphocytic leukemia (ALL), and three patients with advanced myelodysplastic syndrome (MDS). The dose of 131 I delivered to each patient was determined from dosimetry studies, and was escalated in cohorts of three to seven patients to deliver estimated radiation doses of 3.5 Gy to 12.25 Gy to the normal organ receiving the highest dose. Compared to the previous studies employing radiolabeled anti-CD33 antibody, most (84%) patients had favorable biodistribution of mAb, with improved therapeutic ratios of radiation delivered to marrow and spleen as compared to liver (2.3 and 4.8 times higher than liver, respectively). At the maximum tolerated dose (MTD), it was determined that 131 I-anti-CD45 antibody in combination with CY and TBI could deliver an average additional dose of 24 Gy to marrow and 50 Gy to spleen. These studies demonstrated that 131 I-anti-CD45 can deliver substantially greater doses of radiation to hematopoietic tissues as compared with liver, lung or kidney, and that this supplemental radiation can be safely combined with CY and 12 Gy TBI. Although disease-free survival was not an end point of this study, seven of 25 patients (28%) remain disease free for a median of 58 months from transplant.
A follow-up phase II study is underway investigating the use of 131 I-anti-CD45 mAb in a preparative regimen for patients with AML in first remission. 27, 28 Infusion of 131 I-BC8 was administered to the first 32 patients with favorable biodistributions seen in 91% of cases. Twenty-four patients received therapeutic doses of 131 I-BC8 (101-263 mCi) plus standard BU (16 mg/kg) and CY (120 mg/kg). Eighteen of the treated patients (75%) were alive without evidence of disease at 10 to 63 months (median 42 months) after therapy. Leukemic relapse developed in 10% of evaluable patients, and the numbers of grade 3-4 toxicities have been acceptable. These data appear promising since approximately 30% of patients with AML in first remission would be expected to develop leukemic relapse after being treated with standard BU/CY conditioning and stem cell transplantation. 29 Another antigen molecule, CD66, which is also not internalized or shed, has been explored as a target for RIT.
30
CD66 is expressed at high density on normal maturing hematopoietic cells, but is not found on AML blasts. 31, 32 Targeting the CD66 antigen thus delivers cytotoxic radiation to bystander leukemic cells via targeted maturing myeloid cells. Bunjes et al 33 have investigated 188
Re-labeled anti-CD66 mAb as part of conditioning regimens prior to stem cell transplantation in 36 patients with high-risk AML. Disease-free survival (DFS) at 18 months overall was 45%, with patients undergoing transplantation in remission having a significantly higher DFS compared to those patients who were not in remission at the time of transplant (67% vs 31%).
Non-Hodgkin's lymphomas
Non-Hodgkin's lymphomas (NHL) are particularly well suited for RIT as they express a number of well-defined surface antigens, and lymphoma cells are highly radiosensitive, even when resistant to chemotherapy. Radiolabeled mAbs are also not reliant on host immune effector systems, which are generally defective in NHL patients. Radiolabeled antibodies, using both 131 I and 90 Y at non-myeloablative doses, have been used by many groups to target a variety of cell surface antigens (eg CD20, CD21, CD22, CD37, HLA class II molecules; Table 5 I-anti-CD22 followed by autologous stem cell rescue achieved partial remissions. However, the durations of the responses were only 3 and 8 months. More favorable tumor dosimetry has since been seen using 90 Y-anti-CD22 immunoconjugates. 35 Several trials using non-myeloablative doses of either a murine anti-CD20 antibody labeled with 131 I (tositumomab) or a conjugate of the anti-CD20 antibody 2B8 (ibritumomab) and 90 Y (conjugated using the tiuxetan linker) have documented response rates of 60-95%. [36] [37] [38] However, most patients subsequently suffer a relapse and the median progression-free survival is approximately 1 year using 131 I-or 90 Y-labeled anti-CD20 antibody. 37 The Seattle RIT group has evaluated much higher, myeloablative doses of radioimmunoconjugates in the setting of autologous stem cell transplantation for the treatment of relapsed B cell lymphoma patients. An initial phase I trial investigated the role of 131 I-labeled anti-B cell antibodies targeting CD20, CD37, and idiotypic immunoglobulin antigens, followed by autologous hematopoietic stem cell infusion in 37 patients with relapsed B cell NHL. 39 Superior targeting with the anti-CD20 antibody was seen compared with the other antibodies tested in this trial. Massive splenomegaly and large tumor burdens negatively impacted the biodistribution of antibody. A subsequent phase II study was performed in 21 patients under the age of 60 (median age as 47) who received a therapeutic infusion of 131 I-anti-CD20 antibody calculated to deliver 25 to 27 Gy to normal organs, followed by autologous stem cell infusion. 40 
Table 5
Selected trials using myeloablative doses of radioimmunoconjugates and stem cell transplantation to treat non-Hodgkin's lymphomas CR ϭ complete response ϭ no evidence of disease for у1 month; PR ϭ partial response ϭ у50% decrease from baseline in overall tumor size; Cy ϭ cyclophosphamide; VP-16 ϭ etoposide; BEAM ϭ BCNU, etoposide, cytarabine, melphalan; OS ϭ overall survival; PFS ϭ progression-free survival; cGy ϭ centigray; Gy ϭ gray.
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In updated results, high-dose 131 I-anti-CD20 mAb (tositumomab) and autologous stem cell rescue resulted in an 86% response rate with a 79% CR rate. 41 With a median follow-up of 42 months, estimated overall survival (OS) and progression-free survival rates (PFS) were 68% and 42%, respectively. Toxicities were minimal when compared with conventional TBI containing transplantation regimens.
Although these higher doses of RIT may be more efficacious than standard transplant approaches and salvage chemotherapeutic regimens, approximately half of the patients treated subsequently suffered a relapse. Since most neoplastic diseases respond maximally to combinations of chemotherapeutic regimens, a phase I/II study to determine the MTD of 131 I-anti-CD20 antibody that can be given in conjunction with an autologous transplant preparative regimen using high-dose etoposide and cyclophosphamide was performed. 42 This approach was found to be safe at a MTD of 25 Gy, with opportunistic infections being the most serious complication in this protocol. The estimated OS and PFS of the 52 patients treated on this study was 83% and 68%, respectively, at 2 years. Although not primary endpoints for this dose-finding study, the data demonstrating the PFS and OS of patients treated with this high-dose RIT regimen suggest that this approach may be superior to a control group receiving a conventional transplant regimen employing external TBI rather than radiolabeled antibody. 42 Vose et al 43 at the University of Nebraska, have reported on 23 relapsed NHL patients in a phase I/II trial treated with 131 I-tosotumamb at estimated total body doses of 30 to 75 cGy delivered sequentially with high-dose BEAM (BCNU, etoposide, cytarabine, melphalan) therapy and autologous stem cell transplantation. An overall response of 66% was seen with this regimen and 57% of patients achieved a complete response, with a median of 12 months of follow-up. The authors concluded that radiolabeled anti-CD20 antibody can be delivered at standard doses as part of a BEAM high-dose therapy and autologous transplant regimen safely with no delay in engraftment.
Hodgkin's disease
Ferritin is a Hodgkin's disease-associated antigen that has been targeted in separate non-myeloablative RIT trials with modest success. 44 Safety and feasibility trials for the treatment of patients with advanced Hodgkin's disease have also been performed using anti-ferritin immunoglobulin radiolabeled at myeloablative doses with 90 Y, delivered either as stand-alone treatment or in combination with highdose chemotherapy, followed by autologous marrow support. Despite results suggesting that a transplant approach using 90 Y-anti-ferritin alone provides objective responses in approximately half of patients with chemotherapy refractory disease, the majority of survivors studied have developed recurrence of their Hodgkin's disease. 45, 46 Similar results have also been seen using 90 Y-anti-ferritin in combination with high-dose chemotherapy and autologous stem cell transplantation for patients with advanced Hodgkin's disease. 47 It is possible that improved outcomes would be seen in a similar population of patients treated earlier in the course of their disease. The authors suggest that a transplant approach using targeted RIT plus high-dose chemotherapy may provide outcomes that are at least equivalent, and possibly even superior to standard transplant regimens for advanced Hodgkin's disease patients.
Multiple myeloma
Holmium-166-EDTMP is not a true radioimmunoconjugate but a ␤ emitting radiopharmaceutical with high energy complexed to an aminophosphonate ligand that has been shown to be marrow ablative in a canine model, and its effects can be reversed by bone marrow transplantation. 48 166 Ho-DOTMP has recently been investigated in combination with high-dose chemotherapy and TBI, followed by autologous stem cell transplant in 77 patients with multiple myeloma. 49 Patients received 166 Ho-DOTMP in escalating estimated doses to marrow (20-40 Gy, in 10 Gy increments), and were randomized to one of three arms: (1) 140 mg/m 2 melphalan alone, (2) 200 mg/m 2 melphalan alone, or (3) 140 mg/m 2 melphalan plus 8 Gy of TBI. Overall response assessed in 54 evaluable patients across all doses and study arms was 50%, with 43% achieving a complete response. Despite expected myelosuppression, the only significant side-effect potentially attributable to the 166 Ho-DOTMP was hemorrhagic cystitis that developed in 12 patients who did not receive continuous bladder irrigation (CBI) despite hyperhydration and forced diuresis. 50 No significant bladder toxicity was detected in patients who received CBI. The study investigators conclude that the high incidence of hemorrhagic cystitis was most likely to occur in patients receiving the higher doses of 166 Ho-DOTMP with lower associated bone uptake and a higher radiation dose delivered to the bladder.
Radioimmunotherapy of solid tumors
The majority of solid tumor RIT trials targeting a variety of cell surface antigens have employed varying non-myeloablative doses of radioisotopes. Although a small number of solid tumor patients with metastatic chemotherapyrefractory disease have been studied, most patients have developed human anti-mouse antibodies (HAMA), rates of disease response have been low, durations of response have usually been short, and patients have usually developed progressive disease. Whereas non-myeloablative therapy has not been shown to provide any objective responses, some success has been seen for therapy of refractory solid tumors using multimodality therapy combined with myeloablative RIT and autologous stem-cell support (Table 6 ). Tempero et al 51 performed a feasibility trial that evaluated 131 I-labeled CC49 mAb in a setting of hematopoietic stem cell support in patients with metastatic gastrointestinal malignancies. CC49 recognizes a tumor-associated antigen, TAG 72, commonly expressed on many adenocarcinomas, such as colon, lung, ovarian and pancreatic adenocarcinomas. 52 The estimated absorbed dose of radiation at metastatic tumor sites was suboptimal, however, ranging from 630 to 3300 cGy. Examination of tumor biopsy samples indicated that penetration of radiolabeled antibody was limited, likely resulting from heterogeneous antibody uptake.
Radiolabeled mAbs targeting unique epitopes of epithelial glycoprotein mucin (MUC-1), carcinoembryonic antigen (CEA), and murine or chimeric L6 have been investigated in patients with metastatic breast cancer ( Table 6 ). Studies by DeNardo and colleagues at the University of California (Davis, CA, USA) demonstrated the first objective tumor responses using chimeric 131 I-labeled L6 antibody. [53] [54] [55] Additional clinical trials using 90 Y-labeled murine and humanized anti-MUC-1 peptide and carbohydrate mAbs have resulted in approximately half of the patients obtaining an objective improvement in measurable disease. 56 Despite these encouraging results using myeloablative doses of RIT, cures seem unlikely with current methodologies given the inherent radioresistance of many solid tumors. In this regard, synergistic chemotherapeutic agents, such as taxanes that could serve as a radiosensitizing agent, may be important when treating solid tumors with a high-dose RIT approach and are currently being explored.
Conclusions and future directions
Significant principles have been established and encouraging results have been achieved in stem cell transplantation using radioimmunoconjugates targeting antigens found on leukemia and myelodysplastic cells (CD33, CD45, CD66), non-Hodgkin's lymphoma cells (CD20, CD22), and Hodgkin's lymphoma cells (ferritin). Despite the lack of randomized trials comparing transplant regimens with or without the use of radioimmunoconjugates, myeloablative doses of RIT administered in conjunction with stem cell transplantation have provided long-term disease-free survival rates that may be improved over historical controls treated with standard transplant regimens. Advances for patients with solid tumors treated with RIT and autologous transplant, however, have been more difficult to achieve owing to the varying radiosensitivity seen with these malignancies. Therefore, many obstacles must still be overcome to achieve optimal targeting and elimination of tumor cells by radioimmunoconjugates incorporated into transplant conditioning regimens. HAMA ϭ human anti-mouse antibody; SD ϭ stable disease; PR, partial response ϭ у50% decrease from baseline in overall tumor size; MR ϭ minimal response ϭ Ͻ50% decrease from baseline in overall tumor size; PD ϭ progressive disease; NR ϭ no response; CsA ϭ cyclosporine A.
Obstacles to radioimmunotherapy
Heterogeneous antigen expression, variations in rates of catabolism of radiolabeled antibodies in vivo, as well as varying degrees of antigen shedding suggest that alternative antigen-antibody combinations for RIT should be explored more thoroughly (Table 7) . Since tumor cell killing by 131 Iradioimmunoconjugates is directly related to the duration of radionuclide exposure, alternative antibody targets may demonstrate enhanced efficacy for RIT, provided these Table 7 Obstacles to RIT and strategies to overcome them for the successful targeting and elimination of tumor cells by radioimmunoconjugates Bone Marrow Transplantation alternative antigens retain antibodies more avidly than current reagents. An additional obstacle to surmount is the heterogeneous deposition of radiolabeled antibodies within tumors, with preferential accumulation at the periphery of tumors and in perivascular locations. 57 Based on mathematical models, poor antibody penetration into tumors may be limited by antibody-antigen binding constraints. 58, 59 Data from these models suggest that a 'binding site barrier' exists due to the highly effective trapping of high-avidity mAbs by target antigens. The higher the antigen density and the higher the mAb affinity, the greater the binding site barrier, resulting in limited penetration of mAbs to central areas of tumors. 57 High interstitial tumor pressures may also limit tumor penetration, thus inhibiting the delivery of cytotoxic radiation deep into a large mass. 58 Several studies have concluded that smaller fragments penetrate tumors faster, more deeply, and more homogeneously than intact mAbs. 60 On-going work using antigen-binding antibody fragments, such as 'single-chain antibodies' (scFv, ෂ25 kDa) that are smaller than intact immunoglobulin molecules, may serve as a potential targeting option to improve the efficacy of RIT by enhancing penetration deep into tumor sites. 61, 62 The small size and monovalent nature of fragments may be problematic, however, due to potential short tumor retention times and low intratumoral concentrations. 62 The use of radioimmunoconjugates is further complicated by the development of HAMA, which results in additional infusions of mAb being rendered non-functional. The HAMA response can be suppressed by immunomodulatory agents such as cyclosporine, by the use of less immunogenic antibody fragments, by developing a humanized chimeric molecule, or by limiting the infusion of the foreign antibody to one dose.
Obstacles to RIT Strategies to overcome RIT obstacles
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Alternative radioisotopes for RIT In. Recent anti-tumor activity in a non-myeloablative approach has been seen using ␣ emitters such as astatine-211, actinium-225, bismuth-212 and bismuth-213. Studies are on going using these isotopes for the treatment of hematologic malignancies, in particular, leukemias. [63] [64] [65] Alpha particle emitting isotopes are high energy particles capable of a high potency of cell killing and have a very short path length. 66 The use of ␣ emitting isotopes may be particularly advantageous for the targeting of leukemic cells in the marrow, where the short path length could prevent the exposure of normal hematopoietic stem cells to non-specific irradiation. One major disadvantage to the use of currently available ␣ emitting agents, however, is their very short in vivo half-life resulting in a potentially short residence time of the radionuclide.
Pretargeting
The biggest obstacle to the successful targeting and elimination of tumor cells by radioimmunoconjugates using a transplant approach is the suboptimal therapeutic index (risk-to-benefit ratio) currently achievable with conventional RIT methodologies ( Table 7 ). The efficacy of RIT might be improved and the toxicity diminished by improving the delivery of cytotoxic radionuclides to tumor cells while diminishing non-specific radiation to normal organs. The strategy of pretargeting overcomes this obstacle by separating the localization of tumor-specific antibody to sites of disease from the delivery of the therapeutic radionuclide. Figure 1 depicts a potential pre-targeting approach using the high affinity streptavidin (SA)-biotin system where the small radioactive biotin molecule is able to pen- etrate tumor sites rapidly and attach to the pre-targeted antibody bound specifically to tumor cells. If the tumor-bound antibody does not capture this small radioactive molecule, the kidney rapidly excretes it. Recent murine studies using human carcinoma xenografts demonstrate that a single treatment of pretargeted 90 Y-DOTA-biotin results in rapid effective blood clearance of non-tumor-bound antibody, improved tumor-to-normal organ ratios of absorbed radioactivity, and superior complete and durable remissions with minimal toxicity. 67 Our group has recently demonstrated reduced toxicity and markedly enhanced efficacy using pretargeted anti-CD20 antibody compared to the directly labeled anti-CD20 antibody in a mouse xenograft study. 68 A recent non-myeloablative pilot study using anti-CD20-SA conjugate has been performed by Weiden et al 69 for the treatment of patients with relapsed NHL. In this study, a CD20-SA conjugate was delivered to 10 patients, followed 1-2 h later by a synthetic biotinylated clearing agent containing 16 N-acetyl-galactosamine-residues per dendrimeric molecule to eliminate excess mAb-SA molecules from the circulation via hepatic clearance by asialoglycoprotein receptors. 69 Therapeutic 90 Y-biotin was then delivered to patients 3 h after the clearing agent. Objective remissions were seen in four of seven heavily pretreated patients using 30-50 mCi of 90 Y-biotin without significant marrow suppression. It is possible future trials using the pre-targeting approach and stem cell support will deliver even higher doses of radiotherapy to tumor sites, while at the same time exposing normal tissues to lower doses of irradiation. These higher doses of pre-targeted radioimmunotherapy with stem cell rescue may have the most impact on long-term overall and disease-free survival.
